DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1951)

Multiple Myeloma | Landscape & Forecast | Disease Landscape & Forecast

Multiple Myeloma | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Market Outlook

The multiple myeloma landscape is witnessing successive label expansions. The availability of premium-priced branded agents prescribed in doublet and triplet regimens is driving the sales of multiple myeloma drugs. While Celgene’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remain the cornerstones of therapy for multiple myeloma, emerging agents such as Sanofi / ImmunoGen’s isatuximab, Oncopeptides’ Ygalo, Karyopharm Therapeutics’ selinexor, and Bluebird Bio / Celgene’s bb2121 are pursuing initial approvals. There is immense clinical and commercial potential to be exploited in multiple myeloma for therapies that have improved efficacy, novel mechanisms of action, and cater to underserved patient segments.

Questions Answered

  • Revlimid and Velcade are widely used for the current treatment of multiple myeloma, but how will the use of these agents change over the forecast period? What impact will generic entries of these pivotal agents have on the multiple myeloma market?
  • How has the approval of Janssen’s Darzalex and Bristol-Myers Squibb /AbbVie’s Empliciti impacted the multiple myeloma market? How important will these agents become over the forecast period?
  • What are thought leaders’ opinions on agents in Phase III development, such as Sanofi / ImmunoGen’s isatuximab, Bluebird Bio / Celgene’s bb2121, GlaxoSmithKline’s GSK2857916, and Janssen’s subcutaneous formulation of Darzalex?
  • What impact will these agents have on the multiple myeloma market? What are the drivers and constraints in the multiple myeloma market, and how will the market evolve over the forecast period?

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • June 2019
      • December 2018
      • October 2018
      • September 2018
      • May 2018
      • March 2018
      • December 2017
    • Market Outlook
      • Key Findings
        • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Multiple Myeloma?
        • What Factors Are Constraining the Market for Multiple Myeloma?
      • Segment-Specific Trends
        • Smoldering Multiple Myeloma
        • First-Line Transplant-Eligible Multiple Myeloma
        • First-Line Transplant-Ineligible Multiple Myeloma
        • Relapsed/Refractory Multiple Myeloma
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Disease Pathophysiology
        • Overview
      • Risk Factors
      • Staging and Classification
        • Classification of Multiple Myeloma
        • Staging of Multiple Myeloma
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Diagnosed Incident Cases of Multiple Myeloma by Symptoms
        • Asymptomatic Multiple Myeloma Progression to Symptomatic Multiple Myeloma
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Immunomodulatory Agents
        • Proteasome Inhibitors
        • Histone Deacetylase Inhibitors
        • Cell-Surface-Targeted Agents
      • Medical Practice
        • Asymptomatic Multiple Myeloma
        • First-Line Transplant-Eligible Multiple Myeloma
        • First-Line Transplant-Ineligible Multiple Myeloma
        • Relapsed/Refractory Multiple Myeloma
        • Treatment Guidelines
        • Region-Specific Treatment Practices
    • Unmet Need
      • Attainment of Unmet Needs
        • Current and Future Attainment of Unmet Needs in Multiple Myeloma
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Multiple Myeloma
        • Immune Checkpoint Inhibitors
        • Apoptosis-Inducing Agents
        • Cell-Surface-Targeted Agents
        • Selective Inhibitors of Nuclear Export
        • CAR T-Cell Therapies
        • Antibody-Drug Conjugates
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Multiple Myeloma
    • Access and Reimbursement
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
        • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecasting Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Multiple Myeloma Bibliography

Already a Client? Log in to access this report.

  • Pub Date: June 2019
  • Author(s): Snigdha Gupta, Ph.D; Nishant Kumar, MPH
  • Dr. Snigdha Gupta is a Lead Analyst in the oncology team at Decision Resources Group with expertise in multiple oncology indications including non-small cell lung cancer and multiple myeloma. Prior to joining DRG, Dr. Snigdha Gupta was a subject matter expert in immune-oncology, autoimmunity and dealt in generating in-depth framework based scientific analyses for client projects. In her previous organizations, she was involved in the planning and execution of the IND enabling preclinical studies. She has been instrumental in the stage-up of two small molecules at Bioxcel Therapeutics and Daiichi Sankyo Pharma India Pvt. Ltd. Dr. Gupta holds in infectious diseases from the Indian Institute of Chemical Biology, Jadavpur University, Kolkata while her post-doctoral fellowship is from the Mucosal immunology labs of National Institute of Immunology, New Delhi.

  • Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects. His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.

Purchase Report

Recent reports:
You may also be interested in: